Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy

Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.
In a pronouncement that seems to table the prevailing wisdom that any form of hormone replacement remedial programme raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone psychoanalysis might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone psychotherapy is actually protective" in women who have a low risk for developing chest tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver vigrx scriptovore.com. With his colleagues, Ragaz took another aspect at text from the Women's Health Initiative (WHI) study, a native trial that has focused on ways to prevent breast and colorectal cancer, as well as focus disease and fracture risk, in postmenopausal women.

The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by out of doors experts, uncharacteristic studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary fav-store.net. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.

Two groups were limited of the try - women who had had hysterectomies and took estrogen unexcelled as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The mix therapy trial was halted in 2002 after it became clear those women were at increased danger for heart disease and breast cancer.

In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no ex history of benign teat disease had a 43 percent reduction breast cancer risk on estrogen; women with no subdivision history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without above hormone use had a 32 percent reduced risk.

Overall, the 10000-plus participants had a 20 percent reduction in soul cancer risk, a reduction that approached statistical significance. After their review, Ragaz said they concluded that using estrogen alone, strikingly if begun in women less than 60 who don't have a uterus, can aide reduce breast cancer risk.

The new review did not receive medication company funding. "Women without a uterus should be totally safe and benefit a great deal with estrogen-only use ". Yet, more scrutiny is needed to find the best treatment regimen, decide who are the ideal candidates and to figure out certainly why the estrogen only reduces risk in some women.

The findings don't actually include anything new, said Dr Rowan Chlebowski, a WHI investigator who is key of medical oncology/hematology at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The same results were published back in 2006, when the WHI investigators reported on the estrogen-only arm of the study. "These results have been around for a crave era of time". But, he added that "you have to be discreet about interpreting subgroups".

To say estrogen is defensive is a little strong. The overall reduction in breast cancer risk found among the 10000 participants - 20 percent - didn't hold of significance from a statistical sharp end of view. When looked at by subgroups - those with no previous benign breast disease, those with no latest HRT use, those with no first-degree relative with breast cancer - the reductions were significant jaldi weight km kaise kre kya khaye. "The meaning is pretty much unchanged by this new review ," he said, adding "I deem it will get people to look at the data again".